186 related articles for article (PubMed ID: 26362459)
1. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
van der Noll R; Smit WM; Wymenga AN; Boss DS; Grob M; Huitema AD; Rosing H; Tibben MM; Keessen M; Rehorst H; Beijnen JH; Schellens JH
Invest New Drugs; 2015 Dec; 33(6):1197-205. PubMed ID: 26362459
[TBL] [Abstract][Full Text] [Related]
2. A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Park IH; Lee KS; Kang HS; Kim SW; Lee S; Jung SY; Kwon Y; Shin KH; Ko K; Nam BH; Ro J
Invest New Drugs; 2012 Oct; 30(5):1972-7. PubMed ID: 22006161
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
[TBL] [Abstract][Full Text] [Related]
4. Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Cerbone L; Sternberg CN; Sengeløv L; Agerbaek M; Van Herpen C; Marreaud S; Collette S; Zhang J; Daugaard G
Oncology; 2016; 90(1):21-8. PubMed ID: 26468947
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Gómez HL; Neciosup S; Tosello C; Mano M; Bines J; Ismael G; Santi PX; Pinczowski H; Nerón Y; Fanelli M; Fein L; Sampaio C; Lerzo G; Capó A; Zarba JJ; Blajman C; Varela MS; Martínez-Mesa J; Werutsky G; Barrios CH
Clin Breast Cancer; 2016 Feb; 16(1):38-44. PubMed ID: 26642810
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.
Chu QS; Schwartz G; de Bono J; Smith DA; Koch KM; Versola MJ; Pandite L; Arya N; Curtright J; Fleming RA; Ho PT; Rowinsky EK
J Clin Oncol; 2007 Aug; 25(24):3753-8. PubMed ID: 17704424
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Xu BH; Jiang ZF; Chua D; Shao ZM; Luo RC; Wang XJ; Liu DG; Yeo W; Yu SY; Newstat B; Preston A; Martin AM; Chi HD; Wang L
Chin J Cancer; 2011 May; 30(5):327-35. PubMed ID: 21527065
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Francois E; Bennouna J; Chamorey E; Etienne-Grimaldi MC; Renée N; Senellart H; Michel C; Follana P; Mari V; Douillard JY; Milano G
Chemotherapy; 2012; 58(5):371-80. PubMed ID: 23235319
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Bachelot T; Romieu G; Campone M; Diéras V; Cropet C; Dalenc F; Jimenez M; Le Rhun E; Pierga JY; Gonçalves A; Leheurteur M; Domont J; Gutierrez M; Curé H; Ferrero JM; Labbe-Devilliers C
Lancet Oncol; 2013 Jan; 14(1):64-71. PubMed ID: 23122784
[TBL] [Abstract][Full Text] [Related]
11. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.
Iwata H; Fujii H; Masuda N; Mukai H; Nishimura Y; Katsura K; Ellis CE; Gagnon RC; Nakamura S
Breast Cancer; 2015 Mar; 22(2):192-200. PubMed ID: 23689990
[TBL] [Abstract][Full Text] [Related]
13. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Safran H; Miner T; Resnick M; Dipetrillo T; McNulty B; Evans D; Joseph P; Plette A; Millis R; Sears D; Gutman N; Kennedy T
Am J Clin Oncol; 2008 Apr; 31(2):140-4. PubMed ID: 18391597
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
Storniolo AM; Pegram MD; Overmoyer B; Silverman P; Peacock NW; Jones SF; Loftiss J; Arya N; Koch KM; Paul E; Pandite L; Fleming RA; Lebowitz PF; Ho PT; Burris HA
J Clin Oncol; 2008 Jul; 26(20):3317-23. PubMed ID: 18490651
[TBL] [Abstract][Full Text] [Related]
17. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
[TBL] [Abstract][Full Text] [Related]
18. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
19. Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single-institution experience.
Carli P; Militello L; Miolo GM; Quitadamo D; Lombardi D; Torrisi E; Scalone S; Crivellari D; Spazzapan S
Tumori; 2014; 100(6):605-11. PubMed ID: 25688493
[TBL] [Abstract][Full Text] [Related]
20. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]